Related Experiment Videos
Locally advanced non-small cell lung cancer
1Section of Hematology and Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA.
Current Treatment Options in Oncology
|June 12, 2002
Summary
Locally advanced non-small cell lung cancer (NSCLC) management is challenging. Current treatments involve chemotherapy and radiation, with ongoing research into newer, more effective agents and radiation techniques.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Physics
Background:
- Locally advanced non-small cell lung cancer (NSCLC) is paradoxically difficult to manage despite being confined to the thorax.
- While ostensibly curable, most patients with advanced NSCLC succumb to the disease.
- Current standard therapy involves chemotherapy and radiation, but optimal regimens require further definition.
Purpose of the Study:
- To review the current therapeutic landscape for locally advanced non-small cell lung cancer.
- To highlight emerging chemotherapeutic, biologic agents, and advances in radiation therapy for NSCLC.
Main Methods:
- Review of current clinical practices and emerging research in NSCLC treatment.
- Analysis of established and novel chemotherapeutic agents, biologic agents, and radiation therapy techniques.
Main Results:
- Cisplatin is a widely accepted standard cytotoxic drug for advanced NSCLC.
- Newer agents like carboplatin, paclitaxel, gemcitabine, and vinorelbine are gaining approval.
- Radiation therapy is undergoing significant advancements in dose intensity and scheduling.
Conclusions:
- Despite current treatments, advanced NSCLC remains a significant clinical challenge.
- Ongoing research into novel agents and radiation techniques holds promise for improved efficacy and reduced toxicity.
- Future advancements in radiation therapy aim to achieve superior local control for NSCLC patients.